Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

393 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 8 of 9

  1. Vaccine PvCS N+C+R 150 mcg

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 2 mab active

    1 trial

  2. Valproate

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    phase 2 small molecule completed

    1 trial

  3. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

  4. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 small molecule active

    1 trial

  5. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    2 trials

  6. Varenicline Adaptive Protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  7. Venlafaxine

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  8. Venlafaxine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  9. Very Low Nicotine Content Cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence, Cigarettes, Uncomplicated

    phase 2 small molecule completed

    1 trial

  10. Very low nicotine content cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    2 trials

  11. Very low nicotine content cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 2 small molecule completed

    2 trials

  12. Virtual Reality based distraction

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 other completed

    1 trial

  13. Within-Subject test of blinded study medication

    BRIGHT MINDS BIOSCIENCES INC.

    Low Back Pain, Recurrent

    phase 2 small molecule completed

    1 trial

  14. Within-subject test of blinded study medications

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 small molecule completed

    1 trial

  15. Workshop

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  16. X-82

    BRIGHT MINDS BIOSCIENCES INC.

    Age-Related Macular Degeneration (AMD)

    phase 2 small molecule terminated

    1 trial

  17. YMSM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior

    phase 2 other completed

    1 trial

  18. aerobic exercise

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  19. affect regulation training

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 other completed

    1 trial

  20. alprazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Anxiety Disorder

    phase 2 small molecule completed

    1 trial

  21. atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  22. buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 2 small molecule active

    1 trial

  23. buprenorphine taper followed by naltrexone maintenance

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Opioid Dependence

    phase 2 small molecule completed

    1 trial

  24. chantix

    BRIGHT MINDS BIOSCIENCES INC.

    Varenicline and the Blunting of Cocaine Cues

    phase 2 small molecule terminated

    1 trial

  25. chatbot

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate-Related Disorders

    phase 2 other active

    1 trial

  26. citicoline

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  27. clarithromycin

    BRIGHT MINDS BIOSCIENCES INC.

    Relapse/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  28. coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  29. controlled release carvedilol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  30. d-cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    COCAINE-RELATED DISORDERS

    phase 2 small molecule completed

    1 trial

  31. d-cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Panic Disorder

    phase 2 small molecule completed

    1 trial

  32. dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  33. e-cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Nontherapeutic

    phase 2 other completed

    1 trial

  34. employment-based reinforcement

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 2 other completed

    1 trial

  35. empowerment theory-based small group discussion

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    phase 2 other completed

    1 trial

  36. extended-release buprenorphine (BXR)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule on hold

    1 trial

  37. guanfacine-ER

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule completed

    1 trial

  38. l-tetrahydropalmatine (l-THP)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use

    phase 2 small molecule terminated

    1 trial

  39. levetiracetam

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  40. levodopa

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  41. lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  42. metformin

    BRIGHT MINDS BIOSCIENCES INC.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  43. mirtazapine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  44. naltrexone implant

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    2 trials

  45. nicotine transdermal system

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  46. opiates

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule completed

    1 trial

  47. oxycodone 15 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  48. placebo mouthwash

    BRIGHT MINDS BIOSCIENCES INC.

    Dentinal Hypersensitivity

    phase 2 other completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.